AC8
Director Trades
| Date | Director | Value |
|---|
Company News
Drawbacks of the TGA’s cannabis changes for listed pot stocks
Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the ailing masses. But the path to the pharmacy is likely to be harder than they […]
AusCann to begin distributing THC-CBD medicinal cannabis capsules throughout Australia
AusCann Group’s (ASX: AC8) hard shell medicinal cannabis products are now available for prescription Australia-wide, with clinical trials also ready to kick-off into evaluating different doses of its THC-CBD formulations. In parallel with the upcoming clinical study, AusCann has made its medicinal cannabis capsules available to Australian patients via the Therapeutic Goods Administration Special Access […]
AusCann fast-tracks commercialisation of cannabinoid capsules
AusCann Group Holdings (ASX: AC8) is speeding up plans to bring its proprietary cannabinoid-based hard-shell capsules to market, aiming to make them available for patients in Australia before the first half of next year. The medical cannabis company today announced it has completed manufacturing and testing of the capsules and released a commercial-sized batch for […]
AusCann Group finalises purchase of medical cannabis R&D facility in Perth
Medical cannabis company AusCann Group (ASX: AC8) has taken an assertive step into expanding its production business by acquiring a 7,300-square-metre research and development facility in Perth, Western Australia. AusCann says the newly-acquired facility will be used to progress its cannabinoid pharmaceutical product pipeline including the impending production of hard-shell cannabinoid capsules set to take […]
AusCann looks to tighten grip on Latin American medicinal cannabis growth spurt
One of Australia’s most prominent medical cannabis growth stories AusCann (ASX: AC8) has announced that its Chilean joint venture company DayaCann has signed a non-binding memorandum of understanding (MoU) with Canadian medical cannabis company Khiron Life Sciences (TSXV: KHRN). Incorporated in 2014, AusCann holds the full set of necessary licences to grow and manufacture cannabinoid […]
AusCann reports successful study in ‘game changer’ cannabinoid capsules
AusCann (ASX: AC8) is a step closer to releasing its proprietary cannabinoid capsules to world markets after a “successful” pilot study into its optimum final dose. The company has been carrying out the study over the last 10 months, with the aim of launching its medical cannabis products to world markets in the first half […]
AusCann strikes distribution agreement with ASX-listed Australian Pharmaceutical Industries
AusCann Group (ASX: AC8), a leading Australian medicinal cannabis company, has announced a Heads of Agreement (HoA) with ASX-listed Australian Pharmaceutical Industries Limited (ASX: API). The deal will see API distribute AusCann’s cannabinoid medicines throughout Australia and establish long-lasting distribution channels for the supply of AusCann’s medications to Australian patients. News of today’s HoA saw […]
AusCann plants second cannabis crop in Chile
AusCann (ASX: AC8) has announced the planting of a second medicinal cannabis crop in Chile, with harvest expected in the first half of next year. The Australia-based company said its 50%-owned joint venture DayaCann planted the crop at its 30-hectare facility south of Santiago following the grant of a second cultivation licence in late November. The […]
AusCann’s Chilean JV fires up for another year of cannabis cultivation
AusCann Group Holdings (ASX: AC8) has acquired another one-year licence allowing it to cultivate cannabis crops at its 50%-owned facility in Chile. The Chilean facility is held under a 50:50 joint venture between AusCann and Fundacion Daya and the duo, referred to as DayaCann, harvested more than 400kg earlier this year in its first successful […]